• Celebrating women in life sciences and healthcare: insights and challenges from Hannah Kuchler
    Read more
  • Life Sciences A to Z - N is for Navigating the EU Health Data Space
    Read more
  • Stephenson Harwood advises Dr. Falk on acquisition of Kynos Therapeutics
    Read more
  • Stephenson Harwood advises Hong Kong AI business on reverse merger and NASDAQ listing
    Read more
Insights

Celebrating women in life sciences and healthcare: insights and challenges from Hannah Kuchler

Law firm Stephenson Harwood LLP recently held an event for women in life sciences and healthcare, to celebrate International Women's Day and the achievements of women working in the sector. The evening included a fireside chat with the Emmy-nominated, Loeb-winning Hannah Kuchler, Global Pharmaceutical Editor for the Financial Times, and Alexandra Pygall, head of life sciences and healthcare at Stephenson Harwood.

Stephenson Harwood advises Dr. Falk on acquisition of Kynos Therapeutics

Stephenson Harwood LLP has advised Dr. Falk Pharma GmbH ('Dr. Falk'), a German multi-national pharmaceutical company, on its successful acquisition of Kynos Therapeutics Ltd ('Kynos'), a clinical stage biopharmaceutical company focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases.

Stephenson Harwood advises Hong Kong AI business on reverse merger and NASDAQ listing

Stephenson Harwood's Hong Kong corporate team has advised YOOV Group on its proposed reverse merger and listing on NASDAQ.

Stephenson Harwood advises on healthcare data acquisition

Stephenson Harwood LLP has acted for FPE Capital LLP on the acquisition by its portfolio company, Egress, of healthcare data migration specialist Stalis.

Stephenson Harwood advises Lansen Pharmaceutical on privatisation

Stephenson Harwood LLP acted as the Hong Kong legal adviser to Lansen Pharmaceutical Holdings Limited (Lansen Pharmaceutical) on its privatisation by Cathay International Pharma Manufacture And Distribution (China) Limited, involving a total consideration of approximately HK$240 million.

View Insights and news